Multiplatform serum metabolic phenotyping combined with pathway mapping to identify biochemical differences in smokers

Bioanalysis

Volumn 8, Issue 19, 2016, Pages 2023-2043

  Kaluarachchi, Manuja R ^a   Boulangé, Claire L ^a   Garcia Perez, Isabel ^a   Lindon, John C ^a   Minet, Emmanuel F ^b  

^a Metabometrix Ltd   (United Kingdom)

^b BRITISH AMERICAN TOBACCO   (United Kingdom)

Author keywords

biomarker; metabonomics metabolomics; xenobiotics

Indexed keywords

NICOTINE; BIOLOGICAL MARKER; LIPID; LIPOPROTEIN;

ADULT; ADVERSE OUTCOME; ARTICLE; BLOOD ANALYSIS; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE MAPPING; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHENOTYPE; RISK ASSESSMENT; SMOKING; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; BLOOD; CHEMISTRY; CLUSTER ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; METABOLOMICS; MIDDLE AGED; PRINCIPAL COMPONENT ANALYSIS; PROCEDURES; REVERSED PHASE LIQUID CHROMATOGRAPHY; SALIVA; STATISTICAL MODEL; TIME FACTOR; URINE;

ADULT; BIOMARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, REVERSE-PHASE; CLUSTER ANALYSIS; FEMALE; HUMANS; LINEAR MODELS; LIPIDS; LIPOPROTEINS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLOMICS; MIDDLE AGED; NICOTINE; PRINCIPAL COMPONENT ANALYSIS; SALIVA; SMOKING; TIME FACTORS;

EID: 84988566161     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio-2016-0108     Document Type: Article

References (65)

1. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest 123(Suppl. 1), S21-S49 (2003).
2. Diaz-Guzman E, Mannino DM. Epidemiology and prevalence of chronic obstructive pulmonary disease. Clin. Chest Med. 35(1), 7-16 (2014).
3. Paffenbarger RS Jr, Hyde RT, Wing AL, Hsieh C. Cigarette smoking and cardiovascular diseases. IARC Sci. Publ. (74), 45-60 (1986).
4. Hall W, Gartner C, Forlini C. Ethical issues raised by a ban on the sale of electronic nicotine devices. Addiction 110(7), 1061-1067 (2015).
5. Protano C, Di Milia LM, Orsi GB, Vitali M. Electronic cigarette: a threat or an opportunity for public health? State of the art and future perspectives. Clin. Ter. 166(1), 32-37 (2015).
6. Lowe FJ, Luettich K, Gregg EO. Lung cancer biomarkers for the assessment of modified risk tobacco products: an oxidative stress perspective. Biomarkers 18(3), 183-195 (2013).
7. Valavanidis A, Vlachogianni T, Fiotakis C. 8-hydroxy-2?-deoxyguanosine (8-OHdG): a critical biomarker of oxidative stress and carcinogenesis. J. Environ. Sci. Health C. Environ. Carcinog. Ecotoxicol. Rev. 27(2), 120-139 (2009).
8. Ansari S, Baumer K, Boue S et al. Comprehensive systems biology analysis of a 7 month cigarette smoke inhalation study in C57BL/6 mice. Sci. Data 3, 150077 (2016).
9. Phillips B, Veljkovic E, Boue S et al. An 8-Month Systems Toxicology Inhalation/Cessation Study in Apoe-/-mice to investigate cardiovascular and respiratory exposure effects of a candidate modified risk tobacco product, THS 2. 2, compared with conventional cigarettes. Toxicol. Sci. 151(2), 462-464 (2016).
10. Zhu X, Gerstein M, Snyder M. Getting connected: analysis and principles of biological networks. Genes Dev. 21(9), 1010-1024 (2007).
11. Han JD. Understanding biological functions through molecular networks. Cell Res. 18(2), 224-237 (2008).
12. Almaas E. Biological impacts and context of network theory. J. Exp. Biol. 210(Pt 9), 1548-1558 (2007).
13. Vallabhajosyula RR, Raval A. Computational modeling in systems biology. Methods Mol. Biol. 662, 97-120 (2010).
14. Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: beyond biomarkers and towards mechanisms. Nat. Rev. Mol. Cell Biol. 17(7), 451-459 (2016).
15. Dunn WB, Lin W, Broadhurst D et al. Molecular phenotyping of a UK population: defining the human serum metabolome. Metabolomics 11, 9-26 (2015).
16. Garcia-Perez I, Lindon JC, Minet E. Application of CE-MS to a metabonomics study of human urine from cigarette smokers and non-smokers. Bioanalysis 6(20), 2733-2749 (2014).
17. Hsu PC, Zhou B, Zhao Y et al. Feasibility of identifying the tobacco-related global metabolome in blood by UPLC-QTOF-MS. J. Proteome. Res. 12(2), 679-691 (2013).
18. Muller DC, Degen C, Scherer G, Jahreis G, Niessner R, Scherer M. Metabolomics using GC-TOF-MS followed by subsequent GC-FID and HILIC-MS/MS analysis revealed significantly altered fatty acid and phospholipid species profiles in plasma of smokers. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 966, 117-126 (2014).
19. Xu T, Holzapfel C, Dong X et al. Effects of smoking and smoking cessation on human serum metabolite profile: results from the KORA cohort study. BMC Med. 11, 60 (2013).
20. Shepperd CJ, Newland N, Eldridge A, Graff D, Meyer I. A single-blinded, single-centre, controlled study in healthy adult smokers to identify the effects of a reduced toxicant prototype cigarette on biomarkers of exposure and of biological effect versus commercial cigarettes. BMC Public Health 13, 690 (2013).
21. Shepperd CJ, Newland N, Eldridge A et al. Changes in levels of biomarkers of exposure and biological effect in a controlled study of smokers switched from conventional cigarettes to reduced-toxicant-prototype cigarettes. Regul. Toxicol. Pharmacol. 72(2), 273-291 (2015).
22. Banerjee A, Waters D, Camacho OM, Minet E. Quantification of plasma microRNAs in a group of healthy smokers, ex-smokers and non-smokers and correlation to biomarkers of tobacco exposure. Biomarkers 20(2), 123-131 (2015).
23. Haswell LE, Papadopoulou E, Newland N, Shepperd CJ, Lowe FJ. A cross-sectional analysis of candidate biomarkers of biological effect in smokers, never-smokers and ex-smokers. Biomarkers 19(5), 356-367 (2014).
24. European Bioinformatics Institute. www.ebi.ac.uk/metabolights/
25. Want EJ, Wilson ID, Gika H et al. Global metabolic profiling procedures for urine using UPLC-MS. Nat. Protoc. 5(6), 1005-1018 (2010).
26. Dona AC, Jimenez B, Schafer H et al. Precision high-throughput proton NMR spectroscopy of human urine, serum, and plasma for large-scale metabolic phenotyping. Anal. Chem. 86(19), 9887-9894 (2014).
27. Isaac G, McDonald S, Astarita G. Waters application note. www.waters.com
28. Smith CA, Want EJ, O'Maille G, Abagyan R, Siuzdak G. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal. Chem. 78(3), 779-787 (2006).
29. Dieterle F, Ross A, Schlotterbeck G, Senn H. Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics. Anal. Chem. 78(13), 4281-4290 (2006).
30. Petersen M, Dyrby M, Toubro S et al. Quantification of lipoprotein subclasses by proton nuclear magnetic resonance-based partial least-squares regression models. Clin. Chem. 51(8), 1457-1461 (2005).
31. Smith CA, O'Maille G, Want EJ et al. METLIN: a metabolite mass spectral database. Ther. Drug Monit. 27(6), 747-751 (2005).
32. Wishart DS, Jewison T, Guo AC et al. HMDB 3.0-the human metabolome database in 2013. Nucleic Acids Res. 41, D801-D807 (2013).
33. LIPID MAPS, LIPID metabolites and Pathway Strategy, Welcome Trust. www.lipidmaps.org/
34. Sumner LW, Amberg A, Barrett D et al. Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). Metabolomics 3(3), 211-221 (2007).
35. Xia J, Mandal R, Sinelnikov IV, Broadhurst D, Wishart DS. MetaboAnalyst 2.0-a comprehensive server for metabolomic data analysis. Nucleic Acids Res. 40, W127-W133 (2012).
36. Xia J, Sinelnikov IV, Han B, Wishart DS. MetaboAnalyst 3.0-making metabolomics more meaningful. Nucleic Acids Res. 43(W1), W251-W257 (2015).
37. PubChem, NIH. www.pubchem.ncbi.nlm.nih.gov/38 ChEBI (Chemical Entities of Biological Interest), The European Molecular Biology Laboratory. www.ebi.ac.uk/chebi/
38. KEGG (Kyoto Encyclopedia of Genes and Genomres, GenomeNet. www.genome.jp/kegg/
39. Lindon JC, Nicholson JK. Spectroscopic and statistical techniques for information recovery in metabonomics and metabolomics. Annu. Rev. Anal. Chem. (Palo Alto Calif.) 1, 45-69 (2008).
40. Buscher JM, Czernik D, Ewald JC, Sauer U, Zamboni N. Cross-platform comparison of methods for quantitative metabolomics of primary metabolism. Anal. Chem. 81(6), 2135-2143 (2009).
41. Kofeler HC, Fauland A, Rechberger GN, Trotzmuller M. Mass spectrometry based lipidomics: an overview of technological platforms. Metabolites 2(1), 19-38 (2012).
42. Lewis MR, Pearce JTM, Spagou K et al. Development and applicationof UPLC-TOF MS for precision large scale urinarymetabolic phenotyping. Anal. Chem. doi:10.1021/acs. analchem.6b01481 (2016) (Epub ahead of print).
43. Elliott P, Posma JM, Chan Q et al. Urinary metabolic signatures of human adiposity. Sci. Transl. Med. 7, 285 (2015).
44. Ganna A, Salihovic S, Sundstrom J et al. Large-scale metabolomic profiling identifies novel biomarkers for incident coronary heart disease. PLoS. Genet. 10, 12 (2014).
45. Telenga ED, Hoffmann RF, Ruben t et al. Untargeted lipidomic analysis in chronic obstructive pulmonary disease. Uncovering sphingolipids. Am. J. Respir. Crit. Care Med. 190(2), 155-164 (2014).
46. Wang-Sattler R, Yu Y, Mittelstrass K et al. Metabolic profiling reveals distinct variations linked to nicotine consumption in humans-first results from the KORA study. PLoS ONE 3(12), e3863 (2008).
47. Fratta PA, Stranieri C, Pasini A et al. Lysophosphatidylcholine and carotid intima-media thickness in young smokers: a role for oxidized LDL-induced expression of PBMC lipoprotein-associated phospholipase A2? PLoS ONE 8(12), e83092 (2013).
48. Sigruener A, Kleber ME, Heimerl S, Liebisch G, Schmitz G, Maerz W. Glycerophospholipid and sphingolipid species and mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. PLoS ONE 9(1), e85724 (2014).
49. Rozenberg O, Shih DM, Aviram M. Human serum paraoxonase 1 decreases macrophage cholesterol biosynthesis: possible role for its phospholipase-A2-like activity and lysophosphatidylcholine formation. Arterioscler. Thromb. Vasc. Biol. 23(3), 461-467 (2003).
50. Carmena R, Duriez P, Fruchart JC. Atherogenic lipoprotein particles in atherosclerosis. Circulation 109(23 Suppl. 1), 32-37 (2004).
51. Liu ML, Ylitalo K, Nuotio I, Salonen R, Salonen JT, Taskinen MR. Association between carotid intima-media thickness and low-density lipoprotein size and susceptibility of low-density lipoprotein to oxidation in asymptomatic members of familial combined hyperlipidemia families. Stroke 33(5), 1255-1260 (2002).
52. Kwiterovich PO Jr. Lipoprotein heterogeneity: diagnostic and therapeutic implications. Am. J. Cardiol. 90(8A), 1i-10i (2002).
53. Stegemann C, Pechlaner R, Willeit P et al. Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck study. Circulation 129(18), 1821-1831 (2014).
54. Bowler RP, Jacobson S, Cruickshank C et al. Plasma sphingolipids associated with chronic obstructive pulmonary disease phenotypes. Am. J. Respir. Crit. Care Med. 191(3), 275-284 (2015).
55. Goldkorn T, Chung S, Filosto S. Lung cancer and lung injury: the dual role of ceramide. Handb. Exp. Pharmacol. (216), 93-113 (2013).
56. Zhang Y, Li H, Han J, Zhang Y. Down-regulation of microRNA-124 is correlated with tumor metastasis and poor prognosis in patients with lung cancer. Int. J. Clin. Exp. Pathol. 8(2), 1967-1972 (2015).
57. Uhlmann S, Mannsperger H, Zhang JD et al. Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer. Mol. Syst. Biol. 8, 570 (2012).
58. Gu F, Derkach A, Freedman ND et al. Cigarette smoking behaviour and blood metabolomics. Int. J. Epidemiol. pii: dyv330 (2015)(Epub ahead of print).
59. Lin JP, O'Donnell CJ, Schwaiger JP et al. Association between the UGT1A1∗28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation 114(14), 1476-1481 (2006).
60. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science 235(4792), 1043-1046 (1987).
61. Wen CP, Zhang F, Liang D et al. The ability of bilirubin in identifying smokers with higher risk of lung cancer: a large cohort study in conjunction with global metabolomic profiling. Clin. Cancer Res. 21(1), 193-200 (2015).
62. Shimizu H, Kiyohara Y, Kato I et al. Relationship between plasma glutathione levels and cardiovascular disease in a defined population: the Hisayama study. Stroke 35(9), 2072-2077 (2004).
63. Kramer A, Green J, Pollard J Jr., Tugendreich S. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics 30(4), 523-530 (2014).
64. Lai YS, Chen WC, Kuo TC et al. Mass-spectrometry-based serum metabolomics of a C57BL/6J mouse model of high-fat-diet-induced non-alcoholic fatty liver disease development. J. Agric. Food Chem. 63(35), 7873-7884 (2015).
65. Schicho R, Shaykhutdinov R, Ngo J et al. Quantitative metabolomic profiling of serum, plasma, and urine by (1)H NMR spectroscopy discriminates between patients with inflammatory bowel disease and healthy individuals. J. Proteome Res. 11(6), 3344-3357 (2012).